Australia Influenza Vaccine Market Size & Outlook
The influenza vaccine market in Australia is expected to reach a projected revenue of US$ 179.5 million by 2030. A compound annual growth rate of 7.8% is expected of Australia influenza vaccine market from 2024 to 2030.
Revenue, 2023 (US$M)
$106.4
Forecast, 2030 (US$M)
$179.5
CAGR, 2024 - 2030
7.8%
Report Coverage
Australia
Australia influenza vaccine market, 2018-2030 (US$M)
Related Markets
Australia influenza vaccine market highlights
- The Australia influenza vaccine market generated a revenue of USD 106.4 million in 2023 and is expected to reach USD 179.5 million by 2030.
- The Australia market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 106.4 million |
| Market revenue in 2030 | USD 179.5 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Australia accounted for 1.3% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza vaccine market segmentation & scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 91.17% in 2023. Horizon Databook has segmented the Australia influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
- Australia Influenza Vaccine Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Inactivated
- Live Attenuated
- Australia Influenza Vaccine Indication Outlook (Revenue, USD Million, 2018-2030)
- Quadrivalent
- Trivalent
- Australia Influenza Vaccine Age Group Outlook (Revenue, USD Million, 2018-2030)
- Pediatric
- Adult
- Australia Influenza Vaccine Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Injection
- Nasal Spray
- Australia Influenza Vaccine Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospitals & Pharmacy
- Government & Institutional supply
- Other Distribution Channels
Reasons to subscribe to Australia influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Australia influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia influenza vaccine market outlook size, by vaccine type, 2018-2030 (US$M)
Australia Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
